Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center

References

• Willemze R, Jaffe ES, Burg G, et al WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768–3785.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Guitart J, Kuzel TM, Rosen ST. Primary cutaneous lymphomas: a review with current treatment options. Blood Rev 2003;17:131–142.
   PubMed Web of Science ®Google Scholar
• Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoid and Sezary syndrome clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139:857–866.
   PubMed Web of Science ®Google Scholar
• Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999;40:418–425.
   PubMed Web of Science ®Google Scholar
• van Doorn R, Van Haselen CW, van Voorst Vader PC, et al Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504–510.
   PubMed Web of Science ®Google Scholar
• Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a National Cutaneous Lymphoma Foundation Survey. Cancer 2006;107:2504–2511.
   PubMed Web of Science ®Google Scholar
• Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 1994;47:313–317.
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1998;332:323–327.
   Web of Science ®Google Scholar
• Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431–1439.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA. Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007;92:566–567.
   PubMed Web of Science ®Google Scholar
• Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001;3:137–143.
   PubMed Web of Science ®Google Scholar
• Rayandi F, O'Brien S. Alemtuzuamab in CLL and other lymphoid neoplasms. Cancer Invest 2006;24:718–725.
   PubMed Web of Science ®Google Scholar
• Mijovic A, Abdallah A, Pearce L, Tobal K, Mufti GJ. Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimens. Br J Haematol 2008;142:444–452.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Cazin B, Coutre S, et al Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002;20:205–213.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Patti C, et al Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316–2323.
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M, et al A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920–2924.
   PubMed Web of Science ®Google Scholar
• Dearden CE, Matutes E, Cazin B, et al High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98:1721–1726.
   PubMed Web of Science ®Google Scholar
• Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines and subsequent emergence of CD52-deficient cells. Immunology 1998;95:427–436.
   PubMed Web of Science ®Google Scholar
• Heit W, Bujes D, Wiesneth M. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 1986;64:479–486.
   PubMed Web of Science ®Google Scholar
• Lundin J, Osterborg A, Brittinger G. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European study group of CAMPATH-1H treatment in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3257–3263.
   PubMed Web of Science ®Google Scholar
• Lundin J, Hagberg H, Repp R, et al Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fugoides/Sezary syndrome. Blood 2003;101:4267–4272.
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Seymour JF, Wolf M, et al Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 2003;71:250–256.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Alinari L, Tani M, Fina M, Pileri S, Baccarani M. Preliminary observations in a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005;90:702–703.
   PubMed Web of Science ®Google Scholar
• Bernengo MG, Quaglino P, Comessatti A, et al Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007;92:784–794.
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713–1722.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Langerak AW, Brüggemann M, et al Design and standardisation of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 2003;17:2257–2317.
   PubMed Web of Science ®Google Scholar
• Zent CS, Chen JB, Kurten RC, Kaushal GP, Lacy HM, Schichman SA. Alemtuzumab (CAMPATH 1H) dose not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004;28:495–507.
   PubMed Web of Science ®Google Scholar
• Lowenstein H, Shah A, Chant A, Khan A. Different mechanisms of Campath-1H-mediated depletion for CD4+ and CD8+ T cells in peripheral blood. Transpl Int 2006;19:927–936.
   PubMed Web of Science ®Google Scholar
• Kirsch BM, Haidinger M, Zeyda M, et al Alemtuzumab (Campath-1H) induction therapy and dendritic cells: impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol 2006;16:254–257.
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004;104:655–658.
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Pleri A, Tarella C. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphoma: a critical reappraisal of molecular strategies. Leukemia 1999;13:1691–1695.
   PubMed Web of Science ®Google Scholar
• Poszepczynska-Guigne E, Bagot M, Wechsler J, et al Minimal residual disease in mycosis fungoides follow-up can be assessed by polymerase chain reaction. Br J Dermatol 2003;48:265–271.
   Web of Science ®Google Scholar
• Dereure O, Balavoine M, Salles MT, et al Correlations between clinical, histologic, blood, and skin polymerase chain reaction outcome in patients treated for mycosis fungoides. J Invest Dermatol 2003;121:614–617.
   PubMed Web of Science ®Google Scholar